Euclises Pharmaceuticals, Inc.
Euclises exploits the well validated cancer target COX-2 with novel inhibitors that dramatically improve safety & anti-cancer efficacy.
Euclises - founded by Celebrex inventor John Talley - is focused on novel COX-2 inhibitors with improved safety & efficacy allowing effective treatment of many cancers, such as lung, colorectal, & pancreatic. COX-2 in cancer has been appreciated, but older drugs such as Celebrex have not been effectively developed for this. Clinical studies with these, however, have validated both the impact of COX-2 in cancer & biomarkers for patient selection.